Safety Study of CD-NP in Heart Failure

Study Overview
=================
Brief Summary
-----------------
An open-label study designed to determine the safety, tolerability and pharmacodynamics of CD-NP infusions in heart failure patients.

Official Title
-----------------
A Multi-Center, Ascending Dose Trial to Assess the Safety, Pharmacokinetics and Pharmacodynamics of CD-NP Infusions in Patients With Congestive Heart Failure

Conditions
-----------------
Congestive Heart Failure

Intervention / Treatment
-----------------
* Drug: CD-NP


Participation Criteria
=================
Eligibility Criteria
-----------------
Key Inclusion Criteria: Male or female ≥18 years of age diagnosed with NYHA class III or IV heart failure in the last six months Female patients must be post-menopausal or surgically sterile Diagnosed heart failure with left ventricular ejection fraction <40% obtained within the prior 6 months with at least one symptoms or signs of volume overload Key Exclusion Criteria: Women who are pregnant, breast-feeding or of child-bearing potential Clinically unstable patients Major surgical procedures within 30 days of entry Febrile temp > 100 degrees F) Symptomatic carotid disease, critical carotid stenosis, or stroke within 3 months prior to study entry Currently on IV vasoactive support (e.g., heart transplant candidate) History of unexplained syncope within the past 3 months History of organ transplantation Comorbidities such as clinically significant cardiac valvular stenosis, aortic valvular disease, restrictive cardiomyopathy, hypertrophic obstructive cardiomyopathy, constrictive pericarditis, primary pulmonary hypertension, infiltrative disease, uncorrected congenital heart disease, acute coronary syndrome, restrictive heart failure, or any other condition which, in the opinion of the Investigator, would prevent a patient's participation in the study. Participation in a clinical trial of any investigational therapy or device within 30 days prior to randomization. Treatment with nesiritide within 14 days prior to dosing. Inability to effectively communicate with study personnel.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: CD-NP|24 hr intravenous infusion|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| To assess the safety and tolerability of CD-NP infusions in patients with heart failure |  | 28 days | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| To evaluate the effect of CD-NP infusions on urinary flow rate, urinary sodium and potassium excretion |  | 24 hrs | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Heart failure, CD-NP